Effects of combined arginine vasopressin and levosimendan on organ function in ovine septic shock

Critical Care Medicine

Volumn 38, Issue 10, 2010, Pages 2016-2023

  Rehberg, Sebastian ^a   Ertmer, Christian ^a   Vincent, Jean L ^b   Spiegel, Hans U ^a   Köhler, Gabriele ^a   Erren, Michael ^a   Lange, Matthias ^a   Morelli, Andrea ^c   Seisel, Jennifer ^a   Su, Fuhong ^b   Van Aken, Hugo ^a   Traber, Daniel L ^d   Westphal, Martin ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b ERASME HOSPITAL   (Belgium)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

blood flow; multiple organ failure; myocardial function; peritonitis; sepsis; vascular leak

Indexed keywords

3 NITROTYROSINE; ALANINE AMINOTRANSFERASE; AMYLOID A PROTEIN; ARGIPRESSIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; HEME OXYGENASE 1; HETASTARCH; LACTATE DEHYDROGENASE; LEVOSIMENDAN; LUNG ENZYME; NORADRENALIN; SODIUM CHLORIDE; STEROFUNDIN; TROPONIN I; UREA; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN; VASOCONSTRICTOR AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL OXYGEN TENSION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR FUNCTION; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FLUID BALANCE; FLUID THERAPY; HEART LEFT VENTRICLE CONTRACTILITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG ARTERY PRESSURE; LUNG FUNCTION; LUNG VASCULAR RESISTANCE; NONHUMAN; OXYGEN SATURATION; PERITONITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPTIC SHOCK; SHEEP; SURVIVAL RATE; SURVIVAL TIME; UREA BLOOD LEVEL; ANIMAL; BLOOD GAS ANALYSIS; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECTS; ELECTROLYTE BALANCE; HEART CONTRACTION; LUNG; LUNG WEDGE PRESSURE; PATHOPHYSIOLOGY; PHYSIOLOGY; SHOCK, SEPTIC; VASCULAR RESISTANCE;

ANIMALS; ARGININE VASOPRESSIN; BLOOD GAS ANALYSIS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HYDRAZONES; LUNG; MYOCARDIAL CONTRACTION; NOREPINEPHRINE; PULMONARY WEDGE PRESSURE; PYRIDAZINES; SHEEP; SHOCK, SEPTIC; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS; WATER-ELECTROLYTE BALANCE;

EID: 77957236621     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181ef4694     Document Type: Article

References (40)

1. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
2. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345: 588-595
3. Jones SB, Romano FD: Myocardial beta ad-renergic receptor coupling to adenylate cy-clase during developing septic shock. Circ Shock 1990; 30:51-61
4. Russell J, Walley K, Singer J, et al: Vasopres-sin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877-887
5. Lauzier F, Levy B, Lamarre P, et al: Vasopres-sin or norepinephrine in early hyperdynamic septic shock: A randomized clinical trial. Intensive Care Med 2006; 32:1782-1789
6. Luckner G, Dunser MW, Jochberger S, et al: Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 2005; 33:2659-2666
7. Ertmer C, Rehberg S, Westphal M: Vasopres-sin analogues in the treatment of shock states: potential pitfalls. Best Pract Res Clin Anaesthesiol 2008; 22:393-406
8. Vincent JL: The International Sepsis Forum's frontiers in sepsis: High cardiac output should be maintained in severe sepsis. Crit Care 2003; 7:276-278
9. Morelli A, Ertmer C, Lange M, et al: Effects of short-term simultaneous infusion of dobut-amine and terlipressin in patients with septic shock: The DOBUPRESS study. Br J Anaesth 2008; 100:494-503
10. Rehberg S, Ertmer C, Van Aken H, et al: Role of levosimendan in intensive care treatment of myocardial insufficiency. Anaesthesist 2007; 56:30-43
11. Rehberg S, Ertmer C, Kohler G, et al: Role of arginine vasopressin and terlipressin as first-line vasopressor agents in fulminant ovine septic shock. Intensive Care Med 2009; 35: 1286-1296
12. Wang Z, Su F, Rogiers P, et al: Beneficial effects of recombinant human activated protein C in a ewe model of septic shock. Crit Care Med 2007; 35:2594-2600
13. Rehberg S, Enkhbaatar P, Traber DL: Role of the calcium sensitizer levosimendan in peri-operative intensive care medicine. In: Yearbook of Intensive Care and Emergency Medicine. Vincent JL (Ed). Berlin, Heidelberg, New York: Springer, 2009, pp 498-510
14. Toller WG, Stranz C: Levosimendan, a new inotropic and vasodilator agent. Anesthesiol-ogy 2006; 104:556-569
15. Parrillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328:1471-1477
16. Marx G, Pedder S, Smith L, et al: Attenuation of capillary leakage by hydroxyethyl starch (130/0.42) in a porcine model of septic shock. Crit Care Med 2006; 34:3005-3010
17. Traber DL: Selective V1a receptor agonists in experimental septic shock [Abstract]. Crit Care 2007; 11(Suppl 4):P51
18. Parissis JT, Karavidas A, Bistola V, et al: Effects of levosimendan on flow-mediated va-sodilation and soluble adhesion molecules in patients with advanced chronic heart failure. Atherosclerosis 2008; 197:278-282
19. Luckner G, Mayr VD, Jochberger S, et al: Comparison of two dose regimens of erginine vasopressin in advanced vasidilatory shock. Crit Care Med 2007; 35:2280-2285
20. Cunha-Goncalves D, Perez-de-Sa V, Dahm P, et al: Cardiovascular effects of levosimendan in the early stages of endotoxemia. Shock 2007; 28:71-77
21. Cunha-Goncalves D, Perez-de-Sa V, Grins E, et al: Inotropic support during experimental endotoxemic shock: Part I. The effects of levosimendan on splanchnic perfusion. Anesth Analg 2009; 109:1568-1575
22. Holmes CL, Walley KR, Chittock DR, et al: The effects of vasopressin on hemodynamics and renal function in severe septic shock: A case series. Intensive Care Med 2001; 27: 1416-1421
23. Patel BM, Chittock DR, Russell JA, et al: Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthe-siology 2002; 96:576-582
24. Jackson WL, Shorr AF: Vasopressin and cardiac performance. Chest 2002; 121: 1723-1724
25. Simon F, Giudici R, Scheuerle A, et al: Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: A randomized controlled trial. Crit Care 2009; 13:R113
26. Missant C, Rex S, Segers P, et al: Levosimen-dan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunction. Crit Care Med 2007; 35:707-715
27. Westphal M, Morelli A, Van Aken H: Dear levosimendan, the right ventricle will thank you! Crit Care Med 2007; 35:952-953
28. Guarracino F, Cariello C, Danella A, et al: Effect of levosimendan on ventriculo-arterial coupling in patients with ischemic cardiomy-opathy. Acta Anaesthesiol Scand 2007; 51: 1217-1224
29. Moiseyev VS, Poder P, Andrejevs N, et al: Safety and efficacy of a novel calcium sensi-tizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23:1422-1432
30. Sonntag S, Sundberg S, Lehtonen LA, et al: The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004; 43:2177-2182
31. Morelli A, Teboul JL, Maggiore SM, et al: Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: A pilot study. Crit Care Med 2006; 34:2287-2293
32. Morelli A, De Castro S, Teboul JL, et al: Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005; 31: 638-644
33. Asfar P, Hauser B, Ivanyi Z, et al: Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepato-splanchnic perfusion, oxygen exchange, and metabolism. Crit Care Med 2005; 33:373-380
34. Asfar P, Pierrot M, Veal N, et al: Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endo-toxic rats. Crit Care Med 2003; 31:215-220
35. Dubin A, Murias G, Sottile JP, et al: Effects of levosimendan and dobutamine in experimental acute endotoxemia: A preliminary controlled study. Intensive Care Med 2007; 33: 485-494
36. Lange M, Connelly R, Traber DL, et al: Combined neuronal and inducible nitric oxide synthase inhibition in ovine acute lung injury. Crit Care Med 2009; 37:223-229
37. Enkhbaatar P, Connelly R, Wang J, et al: Inhibition of neuronal nitric oxide synthase in ovine model of acute lung injury. Crit Care Med 2009; 37:208-214
38. Hemmelgarn BR, Manns BJ, Lloyd A, et al: Relation between kidney function, protein-uria, and adverse outcomes. JAMA 2010; 303: 423-429
39. Zager RA, Johnson AC, Lund S, et al: Levo-simendan protects against experimental en-dotoxemic acute renal failure. Am J Physiol Renal Physiol 2006; 290:F1453-F1462
40. Kopustinskiene DM, Pollesello P, Saris NE: Levosimendan is a mitochondrial K(ATP) channel opener. Eur J Pharmacol 2001; 428: 311-314